MannKind | MNKD - Stock


MannKind reported $35.31M in Stock for its fiscal quarter ending in December of 2025.





Stock Change Date
Adma Biologics USD 206.46M 9.8M Dec/2025
BioCryst Pharmaceuticals USD 5.4M 166K Dec/2025
Eli Lilly USD 13.74B 1.56B Dec/2025
Halozyme Therapeutics USD 176.48M 9.32M Dec/2025
Insmed USD 132.07M 11.1M Dec/2025
Karyopharm Therapeutics USD 3.97M 1.03M Sep/2025
MacroGenics USD 7.91M 840K Dec/2025
MannKind USD 35.31M 8.34M Dec/2025
Merck USD 6.44B 157M Sep/2025
Novavax USD 11.54M 1.97M Dec/2025
Novo Nordisk DKK 42.85B 2B Mar/2025
Pfizer USD 11.47B 201M Sep/2025
Sanofi EUR 22.69B 1.81B Dec/2025